Lyell Wealth Management LP Grows Position in Zoetis Inc. (NYSE:ZTS)

Lyell Wealth Management LP grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,140 shares of the company’s stock after purchasing an additional 6,460 shares during the quarter. Zoetis makes up approximately 1.1% of Lyell Wealth Management LP’s portfolio, making the stock its 26th biggest position. Lyell Wealth Management LP’s holdings in Zoetis were worth $11,466,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $33,000. Webster Bank N. A. raised its holdings in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter valued at approximately $40,000. LRI Investments LLC bought a new position in shares of Zoetis during the first quarter valued at approximately $43,000. Finally, Ables Iannone Moore & Associates Inc. bought a new position in shares of Zoetis during the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $191.09 on Friday. The stock has a fifty day simple moving average of $182.85 and a two-hundred day simple moving average of $174.32. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market cap of $86.57 billion, a price-to-earnings ratio of 36.82, a price-to-earnings-growth ratio of 2.92 and a beta of 0.88. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period last year, the company earned $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. Research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZTS shares. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research upped their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus restated a “buy” rating and set a $200.00 target price on shares of Zoetis in a report on Tuesday, August 27th. Finally, Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.